Follow-up study of HER-2/neu amplification in primary breast cancer.
Follow-up study of HER-2/neu amplification in primary breast cancer.
复制标题
DOI：
--
复制
发表时间：
1991-02
期刊：
影响因子：
11.2
通讯作者：
G. Clark;W. McGuire
中科院分区：
文献类型：
--
作者：
G. Clark;W. McGuire
对362例乳腺癌患者(其中185例为淋巴结阳性，177例为阴性)进行了HER-2/neu癌基因扩增检测。总的扩增率为33%(结节阴性者为30%；1~3个阳性结节者为31%；3个以上阳性结节者为40%)。基因拷贝数与腋窝淋巴结状态、类固醇受体状态或患者年龄无关，但与原发肿瘤的大小相关性较弱。在单变量或多变量分析中，HER-2/neu基因的扩增与无病生存或总体生存无关。对于结节阴性疾病的患者，结果明确为阴性。虽然结节阳性患者的单变量结果有轻微的统计学意义(P=0.07)，但在多变量分析中没有保留显著意义。因此，虽然HER-2/neu扩增在原发性乳腺癌中可能具有重要的生物学意义，但作为预测临床结果的预后因子，它的作用微乎其微。
Amplification of the HER-2/neu oncogene was determined in 362 tumors from patients with primary breast cancer (185 node-positive patients and 177 node-negative patients). The overall amplification rate was 33% (30% for node-negative patients; 31% for patients with 1-3 positive nodes; 40% for patients with greater than 3 positive nodes). Gene copy number was not associated with axillary lymph node status, steroid receptor status, or patient age but was weakly correlated with the size of the primary tumor. Amplification of the HER-2/neu gene did not correlate with either disease-free or overall survival in univariate or multivariate analyses. The results were unambiguously negative for patients with node-negative disease. Although the univariate results for node-positive patients were marginally significant (P = 0.07), the significance was not retained in multivariate analyses. Thus, while HER-2/neu amplification may be biologically important in primary breast cancer, it will only be of marginal utility as a prognostic factor for predicting clinical outcome.